Market Outlook
The global Gene Editing Drug market size was valued at USD 1295.4 million in 2022 and is forecast to a readjusted size of USD 3274.3 million by 2029 with a CAGR of 14.2% during review period.
Gene editing drugs are an innovative biomedical treatment method that treat diseases by directly modifying a patient's genes. These drugs use various gene editing technologies, such as CRISPR-Cas9, ZFN (zinc finger nuclease), to precisely edit the patient's DNA sequence. Overall, the field of gene-editing drugs has great potential to treat a variety of diseases, but the field will continue to evolve and advance as ethical, safety, and legal issues are addressed.
Report includes an overview of the development of the Gene Editing Drug industry chain, the market status of General Hospital (CRISPR-Cas9 Gene Editing Drugs, Zinc Finger Nuclease Gene Editing Drugs), Specialty Hospital (CRISPR-Cas9 Gene Editing Drugs, Zinc Finger Nuclease Gene Editing Drugs), and key enterprises in developed and developing market, and analyzed the cutting-edge technology, patent, hot applications and market trends of Gene Editing Drug.
Regionally, the report analyzes the Gene Editing Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Gene Editing Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Gene Editing Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Gene Editing Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., CRISPR-Cas9 Gene Editing Drugs, Zinc Finger Nuclease Gene Editing Drugs).
Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Gene Editing Drug market.
Regional Analysis: The report involves examining the Gene Editing Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Gene Editing Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Gene Editing Drug:
Company Analysis: Report covers individual Gene Editing Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Gene Editing Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (General Hospital, Specialty Hospital).
Technology Analysis: Report covers specific technologies relevant to Gene Editing Drug. It assesses the current state, advancements, and potential future developments in Gene Editing Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Gene Editing Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Key Market Players
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Sangamo Therapeutics
Bluebird Bio
Beam Therapeutics
Yaotang Biotechnology
ICamuno Biotherapeutics
Reforgene Medicine
Star Eyed Creature
Segmentation By Type
CRISPR-Cas9 Gene Editing Drugs
Zinc Finger Nuclease Gene Editing Drugs
Others
Segmentation By Application
General Hospital
Specialty Hospital
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the gene editing drug market in 2025?
The strengths of the gene editing drug market in 2025 include rapid advancements in CRISPR and other gene-editing technologies, increasing investment in R&D, and a growing pipeline of gene editing-based therapies. Regulatory frameworks are maturing, and patient awareness about personalized medicine is driving demand.
What are the weaknesses of the gene editing drug market in 2025?
The market's weaknesses lie in high development costs, complex regulatory hurdles, and ethical concerns about gene editing's societal implications. Additionally, manufacturing scalability and potential off-target effects remain significant technical challenges.
What opportunities does the gene editing drug market have in 2025?
The market has opportunities in expanding applications for rare genetic diseases, oncology, and chronic conditions. Partnerships between biotech companies and academic institutions, as well as government support for innovative treatments, create room for growth. Emerging markets also present untapped potential due to increasing healthcare access.
What are the threats to the gene editing drug market in 2025?
Threats include potential backlash from ethical and religious groups, legal challenges over intellectual property, and competition from alternative therapeutic modalities like RNA-based therapies. Market instability and varying international regulations could also impact global adoption.
Market PESTEL Analysis
What are the political factors impacting the gene editing drug market in 2025?
Political factors include government policies supporting biotech innovation, funding for genetic research, and international cooperation on regulatory standards. However, political instability in certain regions and ethical debates may create barriers.
What are the economic factors influencing the gene editing drug market in 2025?
Economic factors involve significant R&D investment requirements, high treatment costs limiting access in low-income regions, and the potential for strong market growth in emerging economies. Economic downturns or funding cuts could slow progress.
What are the social factors shaping the gene editing drug market in 2025?
Social factors include growing public awareness of genetic therapies, rising demand for personalized medicine, and concerns over the ethical implications of gene editing. Public acceptance varies by culture and societal norms.
What are the technological factors driving the gene editing drug market in 2025?
Technological factors encompass advancements in CRISPR, base editing, and delivery systems. Innovations in AI for drug discovery and improved gene-editing accuracy enhance development. However, keeping up with rapid technological change can be challenging for smaller players.
What are the environmental factors affecting the gene editing drug market in 2025?
Environmental factors include the need for sustainable manufacturing practices and concerns about the environmental impact of production. Additionally, climate change may influence disease patterns, indirectly shaping market demands.
What are the legal factors impacting the gene editing drug market in 2025?
Legal factors involve intellectual property rights, evolving regulatory standards for gene therapies, and potential liability issues related to off-target effects. Global differences in legal frameworks create complexity for multinational operations.
Market SIPOC Analysis
Who are the suppliers in the gene editing drug market in 2025?
Suppliers include biotech companies providing gene editing tools, research institutions advancing CRISPR technologies, and manufacturers of specialized reagents and equipment. Additionally, regulatory bodies contribute by providing necessary approvals and guidelines.
What inputs are required in the gene editing drug market in 2025?
Key inputs are advanced gene editing technologies (such as CRISPR), funding for research and development, genetic data, skilled scientists and medical professionals, and regulatory approvals. Also, patient data and clinical trial results are crucial for progressing therapies.
What processes are involved in the gene editing drug market in 2025?
Processes include drug discovery, gene editing and modification, preclinical and clinical trials, regulatory approvals, and manufacturing of gene-edited drugs. Ongoing monitoring of safety and efficacy, as well as post-market surveillance, are essential steps.
Who are the customers in the gene editing drug market in 2025?
Customers include healthcare providers, hospitals, research institutions, pharmaceutical companies, and patients seeking personalized medicine or treatment for genetic disorders. Investors and regulators are also key stakeholders, shaping market dynamics.
What are the outputs in the gene editing drug market in 2025?
Outputs are gene-edited therapies, clinical trial data, regulatory approval for drugs, and innovative gene-based treatments for various genetic disorders. The market also produces scientific publications, patents, and technological advancements.
Market Porter's Five Forces
What is the level of competitive rivalry in the gene editing drug market in 2025?
The competitive rivalry is high due to the presence of established pharmaceutical giants, innovative biotech startups, and academic institutions. Intense R&D efforts and the race for intellectual property rights further escalate competition.
What is the threat of new entrants in the gene editing drug market in 2025?
The threat of new entrants is moderate due to high entry barriers, including significant R&D costs, regulatory complexities, and the need for specialized expertise. However, advancements in technology and venture capital support can enable niche players to enter the market.
What is the bargaining power of suppliers in the gene editing drug market in 2025?
The bargaining power of suppliers is moderate to high, as they provide critical technologies, tools, and raw materials. Suppliers specializing in gene editing tools like CRISPR hold substantial influence due to the limited number of alternative providers.
What is the bargaining power of buyers in the gene editing drug market in 2025?
The bargaining power of buyers is moderate, as patients, healthcare providers, and payers demand effective and cost-efficient treatments. However, limited alternatives for treating rare genetic disorders reduce buyer influence.
What is the threat of substitutes in the gene editing drug market in 2025?
The threat of substitutes is moderate, as alternative therapies such as RNA-based treatments, stem cell therapies, and traditional pharmaceuticals may compete with gene-edited drugs. However, the unique capabilities of gene editing for targeted interventions make direct substitutes limited.
Market Upstream Analysis
What are the key upstream activities in the gene editing drug market in 2025?
Key upstream activities include the development of gene editing technologies like CRISPR, sourcing high-quality reagents and raw materials, and conducting preclinical research. Collaborations between biotech firms, academic institutions, and suppliers are crucial at this stage.
Who are the major upstream players in the gene editing drug market in 2025?
Major upstream players are technology providers specializing in gene editing tools, reagent manufacturers, contract research organizations (CROs), and academic research labs contributing foundational scientific knowledge.
What raw materials are essential in the gene editing drug market in 2025?
Essential raw materials include DNA/RNA nucleotides, viral vectors for gene delivery, specialized enzymes like Cas proteins, and other biochemical reagents critical for gene editing processes.
What challenges exist in the upstream segment of the gene editing drug market in 2025?
Challenges include ensuring consistent supply chain quality, high costs of specialized materials, scalability of production, and addressing ethical concerns in sourcing certain biological materials.
How do upstream activities influence the downstream outcomes in the gene editing drug market in 2025?
Upstream activities determine the quality, safety, and efficacy of gene editing drugs. Innovations and efficiencies in the upstream segment significantly impact the success of clinical trials, regulatory approval processes, and market readiness of therapies.
Market Midstream Analysis
What are the key midstream activities in the gene editing drug market in 2025?
Key midstream activities include scaling up production processes, conducting clinical trials, obtaining regulatory approvals, and refining gene editing techniques for safety and efficacy. Collaboration between biotech firms and clinical research organizations is critical.
Who are the main midstream players in the gene editing drug market in 2025?
Main midstream players include biotech and pharmaceutical companies, contract manufacturing organizations (CMOs), regulatory agencies, and clinical research organizations (CROs) that manage trials and compliance.
What technologies are important in midstream processes for the gene editing drug market in 2025?
Important technologies include CRISPR and base-editing platforms, advanced gene delivery systems, AI-driven analytics for clinical trial optimization, and biomanufacturing platforms for scalable and precise drug production.
What challenges exist in the midstream segment of the gene editing drug market in 2025?
Challenges include managing the high costs and timelines of clinical trials, addressing potential safety concerns like off-target effects, and navigating complex regulatory landscapes across different regions.
How does the midstream segment impact the gene editing drug market’s success in 2025?
The midstream segment determines the market readiness of gene editing drugs by validating their safety, efficacy, and scalability. Success in this phase directly impacts the ability to secure approvals, gain investor confidence, and meet patient needs.
Market Downstream Analysis
What are the key downstream activities in the gene editing drug market in 2025?
Key downstream activities include distribution of gene editing drugs, market launch strategies, patient education, and ongoing post-market surveillance to monitor safety and efficacy.
Who are the main downstream players in the gene editing drug market in 2025?
Main downstream players include pharmaceutical distributors, healthcare providers, hospitals, clinics, and patient advocacy groups. Insurers and regulatory bodies also play a role in ensuring market access and affordability.
What challenges exist in the downstream segment of the gene editing drug market in 2025?
Challenges include high costs limiting patient access, uneven global distribution networks, regulatory variations between countries, and the need for robust patient support programs to address concerns and improve adoption.
How is patient education important in the downstream segment of the gene editing drug market in 2025?
Patient education is critical for building trust and acceptance, especially given the complexities of gene editing therapies. Transparent communication about benefits, risks, and costs ensures informed decision-making and broader adoption.
What downstream factors influence the success of the gene editing drug market in 2025?
Downstream success depends on effective distribution channels, affordable pricing models, acceptance by healthcare providers and patients, and continuous monitoring to ensure safety and public confidence in the therapies.
Chapter 1, to describe Gene Editing Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Gene Editing Drug, with price, sales, revenue and global market share of Gene Editing Drug from 2018 to 2023.
Chapter 3, the Gene Editing Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gene Editing Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Gene Editing Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Gene Editing Drug.
Chapter 14 and 15, to describe Gene Editing Drug sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Gene Editing Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Gene Editing Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 CRISPR-Cas9 Gene Editing Drugs
1.3.3 Zinc Finger Nuclease Gene Editing Drugs
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Gene Editing Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 General Hospital
1.4.3 Specialty Hospital
1.5 Global Gene Editing Drug Market Size & Forecast
1.5.1 Global Gene Editing Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Gene Editing Drug Sales Quantity (2018-2029)
1.5.3 Global Gene Editing Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 CRISPR Therapeutics
2.1.1 CRISPR Therapeutics Details
2.1.2 CRISPR Therapeutics Major Business
2.1.3 CRISPR Therapeutics Gene Editing Drug Product and Services
2.1.4 CRISPR Therapeutics Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 CRISPR Therapeutics Recent Developments/Updates
2.2 Editas Medicine
2.2.1 Editas Medicine Details
2.2.2 Editas Medicine Major Business
2.2.3 Editas Medicine Gene Editing Drug Product and Services
2.2.4 Editas Medicine Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Editas Medicine Recent Developments/Updates
2.3 Intellia Therapeutics
2.3.1 Intellia Therapeutics Details
2.3.2 Intellia Therapeutics Major Business
2.3.3 Intellia Therapeutics Gene Editing Drug Product and Services
2.3.4 Intellia Therapeutics Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Intellia Therapeutics Recent Developments/Updates
2.4 Sangamo Therapeutics
2.4.1 Sangamo Therapeutics Details
2.4.2 Sangamo Therapeutics Major Business
2.4.3 Sangamo Therapeutics Gene Editing Drug Product and Services
2.4.4 Sangamo Therapeutics Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sangamo Therapeutics Recent Developments/Updates
2.5 Bluebird Bio
2.5.1 Bluebird Bio Details
2.5.2 Bluebird Bio Major Business
2.5.3 Bluebird Bio Gene Editing Drug Product and Services
2.5.4 Bluebird Bio Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Bluebird Bio Recent Developments/Updates
2.6 Beam Therapeutics
2.6.1 Beam Therapeutics Details
2.6.2 Beam Therapeutics Major Business
2.6.3 Beam Therapeutics Gene Editing Drug Product and Services
2.6.4 Beam Therapeutics Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Beam Therapeutics Recent Developments/Updates
2.7 Yaotang Biotechnology
2.7.1 Yaotang Biotechnology Details
2.7.2 Yaotang Biotechnology Major Business
2.7.3 Yaotang Biotechnology Gene Editing Drug Product and Services
2.7.4 Yaotang Biotechnology Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Yaotang Biotechnology Recent Developments/Updates
2.8 ICamuno Biotherapeutics
2.8.1 ICamuno Biotherapeutics Details
2.8.2 ICamuno Biotherapeutics Major Business
2.8.3 ICamuno Biotherapeutics Gene Editing Drug Product and Services
2.8.4 ICamuno Biotherapeutics Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 ICamuno Biotherapeutics Recent Developments/Updates
2.9 Reforgene Medicine
2.9.1 Reforgene Medicine Details
2.9.2 Reforgene Medicine Major Business
2.9.3 Reforgene Medicine Gene Editing Drug Product and Services
2.9.4 Reforgene Medicine Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Reforgene Medicine Recent Developments/Updates
2.10 Star Eyed Creature
2.10.1 Star Eyed Creature Details
2.10.2 Star Eyed Creature Major Business
2.10.3 Star Eyed Creature Gene Editing Drug Product and Services
2.10.4 Star Eyed Creature Gene Editing Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Star Eyed Creature Recent Developments/Updates
3 Competitive Environment: Gene Editing Drug by Manufacturer
3.1 Global Gene Editing Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Gene Editing Drug Revenue by Manufacturer (2018-2023)
3.3 Global Gene Editing Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Gene Editing Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Gene Editing Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Gene Editing Drug Manufacturer Market Share in 2022
3.5 Gene Editing Drug Market: Overall Company Footprint Analysis
3.5.1 Gene Editing Drug Market: Region Footprint
3.5.2 Gene Editing Drug Market: Company Product Type Footprint
3.5.3 Gene Editing Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Gene Editing Drug Market Size by Region
4.1.1 Global Gene Editing Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Gene Editing Drug Consumption Value by Region (2018-2029)
4.1.3 Global Gene Editing Drug Average Price by Region (2018-2029)
4.2 North America Gene Editing Drug Consumption Value (2018-2029)
4.3 Europe Gene Editing Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Gene Editing Drug Consumption Value (2018-2029)
4.5 South America Gene Editing Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Gene Editing Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Gene Editing Drug Sales Quantity by Type (2018-2029)
5.2 Global Gene Editing Drug Consumption Value by Type (2018-2029)
5.3 Global Gene Editing Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Gene Editing Drug Sales Quantity by Application (2018-2029)
6.2 Global Gene Editing Drug Consumption Value by Application (2018-2029)
6.3 Global Gene Editing Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Gene Editing Drug Sales Quantity by Type (2018-2029)
7.2 North America Gene Editing Drug Sales Quantity by Application (2018-2029)
7.3 North America Gene Editing Drug Market Size by Country
7.3.1 North America Gene Editing Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Gene Editing Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Gene Editing Drug Sales Quantity by Type (2018-2029)
8.2 Europe Gene Editing Drug Sales Quantity by Application (2018-2029)
8.3 Europe Gene Editing Drug Market Size by Country
8.3.1 Europe Gene Editing Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Gene Editing Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Gene Editing Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Gene Editing Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Gene Editing Drug Market Size by Region
9.3.1 Asia-Pacific Gene Editing Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Gene Editing Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Gene Editing Drug Sales Quantity by Type (2018-2029)
10.2 South America Gene Editing Drug Sales Quantity by Application (2018-2029)
10.3 South America Gene Editing Drug Market Size by Country
10.3.1 South America Gene Editing Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Gene Editing Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Gene Editing Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Gene Editing Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Gene Editing Drug Market Size by Country
11.3.1 Middle East & Africa Gene Editing Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Gene Editing Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Gene Editing Drug Market Drivers
12.2 Gene Editing Drug Market Restraints
12.3 Gene Editing Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Gene Editing Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Gene Editing Drug
13.3 Gene Editing Drug Production Process
13.4 Gene Editing Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Gene Editing Drug Typical Distributors
14.3 Gene Editing Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Gene Editing Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gene Editing Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. CRISPR Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. CRISPR Therapeutics Major Business
Table 5. CRISPR Therapeutics Gene Editing Drug Product and Services
Table 6. CRISPR Therapeutics Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. CRISPR Therapeutics Recent Developments/Updates
Table 8. Editas Medicine Basic Information, Manufacturing Base and Competitors
Table 9. Editas Medicine Major Business
Table 10. Editas Medicine Gene Editing Drug Product and Services
Table 11. Editas Medicine Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Editas Medicine Recent Developments/Updates
Table 13. Intellia Therapeutics Basic Information, Manufacturing Base and Competitors
Table 14. Intellia Therapeutics Major Business
Table 15. Intellia Therapeutics Gene Editing Drug Product and Services
Table 16. Intellia Therapeutics Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Intellia Therapeutics Recent Developments/Updates
Table 18. Sangamo Therapeutics Basic Information, Manufacturing Base and Competitors
Table 19. Sangamo Therapeutics Major Business
Table 20. Sangamo Therapeutics Gene Editing Drug Product and Services
Table 21. Sangamo Therapeutics Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Sangamo Therapeutics Recent Developments/Updates
Table 23. Bluebird Bio Basic Information, Manufacturing Base and Competitors
Table 24. Bluebird Bio Major Business
Table 25. Bluebird Bio Gene Editing Drug Product and Services
Table 26. Bluebird Bio Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Bluebird Bio Recent Developments/Updates
Table 28. Beam Therapeutics Basic Information, Manufacturing Base and Competitors
Table 29. Beam Therapeutics Major Business
Table 30. Beam Therapeutics Gene Editing Drug Product and Services
Table 31. Beam Therapeutics Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Beam Therapeutics Recent Developments/Updates
Table 33. Yaotang Biotechnology Basic Information, Manufacturing Base and Competitors
Table 34. Yaotang Biotechnology Major Business
Table 35. Yaotang Biotechnology Gene Editing Drug Product and Services
Table 36. Yaotang Biotechnology Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Yaotang Biotechnology Recent Developments/Updates
Table 38. ICamuno Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 39. ICamuno Biotherapeutics Major Business
Table 40. ICamuno Biotherapeutics Gene Editing Drug Product and Services
Table 41. ICamuno Biotherapeutics Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. ICamuno Biotherapeutics Recent Developments/Updates
Table 43. Reforgene Medicine Basic Information, Manufacturing Base and Competitors
Table 44. Reforgene Medicine Major Business
Table 45. Reforgene Medicine Gene Editing Drug Product and Services
Table 46. Reforgene Medicine Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Reforgene Medicine Recent Developments/Updates
Table 48. Star Eyed Creature Basic Information, Manufacturing Base and Competitors
Table 49. Star Eyed Creature Major Business
Table 50. Star Eyed Creature Gene Editing Drug Product and Services
Table 51. Star Eyed Creature Gene Editing Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Star Eyed Creature Recent Developments/Updates
Table 53. Global Gene Editing Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Gene Editing Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Gene Editing Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Gene Editing Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Gene Editing Drug Production Site of Key Manufacturer
Table 58. Gene Editing Drug Market: Company Product Type Footprint
Table 59. Gene Editing Drug Market: Company Product Application Footprint
Table 60. Gene Editing Drug New Market Entrants and Barriers to Market Entry
Table 61. Gene Editing Drug Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Gene Editing Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Gene Editing Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Gene Editing Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Gene Editing Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Gene Editing Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Gene Editing Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Gene Editing Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Gene Editing Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Gene Editing Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Gene Editing Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Gene Editing Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Gene Editing Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Gene Editing Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Gene Editing Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Gene Editing Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Gene Editing Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Gene Editing Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Gene Editing Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Gene Editing Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Gene Editing Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Gene Editing Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Gene Editing Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Gene Editing Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Gene Editing Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Gene Editing Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Gene Editing Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Gene Editing Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Gene Editing Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Gene Editing Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Gene Editing Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Gene Editing Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Gene Editing Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Gene Editing Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Gene Editing Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Gene Editing Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Gene Editing Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Gene Editing Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Gene Editing Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Gene Editing Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Gene Editing Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Gene Editing Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Gene Editing Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Gene Editing Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Gene Editing Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Gene Editing Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Gene Editing Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Gene Editing Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Gene Editing Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Gene Editing Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Gene Editing Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Gene Editing Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Gene Editing Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Gene Editing Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Gene Editing Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Gene Editing Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Gene Editing Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Gene Editing Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Gene Editing Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Gene Editing Drug Raw Material
Table 121. Key Manufacturers of Gene Editing Drug Raw Materials
Table 122. Gene Editing Drug Typical Distributors
Table 123. Gene Editing Drug Typical Customers
List of Figures
Figure 1. Gene Editing Drug Picture
Figure 2. Global Gene Editing Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gene Editing Drug Consumption Value Market Share by Type in 2022
Figure 4. CRISPR-Cas9 Gene Editing Drugs Examples
Figure 5. Zinc Finger Nuclease Gene Editing Drugs Examples
Figure 6. Others Examples
Figure 7. Global Gene Editing Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Gene Editing Drug Consumption Value Market Share by Application in 2022
Figure 9. General Hospital Examples
Figure 10. Specialty Hospital Examples
Figure 11. Global Gene Editing Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Gene Editing Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Gene Editing Drug Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Gene Editing Drug Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Gene Editing Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Gene Editing Drug Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Gene Editing Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Gene Editing Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Gene Editing Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Gene Editing Drug Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Gene Editing Drug Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Gene Editing Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Gene Editing Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Gene Editing Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Gene Editing Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Gene Editing Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Gene Editing Drug Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Gene Editing Drug Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Gene Editing Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Gene Editing Drug Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Gene Editing Drug Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Gene Editing Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Gene Editing Drug Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Gene Editing Drug Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Gene Editing Drug Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Gene Editing Drug Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Gene Editing Drug Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Gene Editing Drug Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Gene Editing Drug Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Gene Editing Drug Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Gene Editing Drug Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Gene Editing Drug Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Gene Editing Drug Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Gene Editing Drug Consumption Value Market Share by Region (2018-2029)
Figure 53. China Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Gene Editing Drug Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Gene Editing Drug Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Gene Editing Drug Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Gene Editing Drug Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Gene Editing Drug Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Gene Editing Drug Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Gene Editing Drug Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Gene Editing Drug Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Gene Editing Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Gene Editing Drug Market Drivers
Figure 74. Gene Editing Drug Market Restraints
Figure 75. Gene Editing Drug Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Gene Editing Drug in 2022
Figure 78. Manufacturing Process Analysis of Gene Editing Drug
Figure 79. Gene Editing Drug Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
